

## **INFLUENZA VACCINE**

Recommendations from Advisory  
Committee on Vaccines & Immunization  
Practices\*

### **For routine vaccination:**

**Minimum age for vaccination is 6 months for inactivated influenza vaccine (IIV) and 2 years for live, attenuated influenza vaccine (LAIV).**

### **Time of vaccination as per hemispheric recommendations:**

- It is recommended to use the most recent strain formulation of the vaccine, irrespective of the hemispheric recommendation.
- The best time to vaccinate is before the onset of peak influenza activity, which is usually seen throughout the year in India with a clear peaking during the rainy season all over the country.
- The extreme northern part of India has a peak in cooler winter months, while the rainy season in India is between June to August in all the regions except Tamil Nadu where it occurs from October to December.
- Hence, the optimum time to vaccinate is the pre-monsoon period, May-June, with the latest available strain, which is the Southern Hemisphere (SH) strain.
- The World Health Organization (WHO) classifies India under the 'South Asia' transmission zone of influenza circulation which is more aligned with the Southern Hemisphere (SH) strains.

**Quadrivalent IIV is preferred over trivalent IIV**

## Recommendations for IIV

- IIV is recommended for all children 6 months to 5 years and for persons with certain high-risk conditions between 6 to 18 years.
- High-risk conditions include chronic cardiac, respiratory, hematological, renal conditions, chronic liver disease, diabetes mellitus, congenital and acquired immunodeficiency, children on long-term salicylates, laboratory personnel, and healthcare providers.

## Recommendations for LAIV

- LAIV is recommended for only healthy children aged 2-18 years, and for most healthy children aged 2 through 18 years, either LAIV or IIV may be used.
- LAIV should not be administered to children who have experienced severe allergic reactions to LAIV or any of its components, or to a previous dose of any other influenza vaccine, children 2 through 17 years receiving aspirin or aspirin-containing products, children with immunodeficiency, children 2 through 4 years of age with asthma or who had wheezing in the past 12 months, and children with chronic medical conditions.

## Dosage recommendations:

- First-time vaccination for IIV is recommended for 6 months to below 9 years, with two doses 4 weeks apart, while 9 years and above require a single dose.
- Annual revaccination with a single dose is recommended for both IIV and LAIV.
- Dosage for IIV is 6 months onwards: 0.5 ml (15mcg/0.5ml), while for LAIV, see the product insert of the available formulation.
- Any child less than 9 years of age who has received less than two doses in the past should receive two doses again in this season, while any child less than 9 years of age who has received at least 2 doses in the past and the 2 doses may not have been given in the same season should receive one dose in this season.

**FluQuadri® is an inactivated quadrivalent inactivated influenza vaccine (SPLIT VIRION) I.P. SH- 2023.** FluQuadri® is indicated for the prevention of influenza disease caused by influenza types A and B viruses contained in the vaccine.

**Each dose of 0.5ml contains:**


A/Sydney/5/2021 (H1N1) pdm09 - like strain.....15 mcg hemagglutinin  
 A/Darwin/9/2021 (H3N2) - like strain).....15 mcg hemagglutinin  
 B/Austria/1359417/2021- (B/Victoria lineage)- like strain...15 mcg hemagglutinin  
 B/Phuket/3073/2013- (B/Yamagata lineage)- like strain.15 mcg hemagglutinin

**with other inactive ingredients**

Age	Dose	Schedule
6 months through 35 months	One or two doses <sup>a</sup> , 0.5 ml each	If 2 doses, administer at least 4 weeks apart
36 months through 8 years	One or two doses <sup>a</sup> , 0.5 ml each	If 2 doses, administer at least 4 weeks apart
9 years and older	One dose, 0.5ml	-

a 1 or 2 doses depends on vaccination history as per Advisory Committee on Immunization Practices annual recommendations on prevention and control of influenza with vaccines.


**(Please refer to PI on [www.Sanofi.in](http://www.Sanofi.in) if more information is required)**



For the use of Registered Medical Practitioner only


**sanofi**

**When Risk of Influenza is at its Peak,  
what one needs is Peak Protection**



**FluQuadri®**  
Quadrivalent Inactivated Influenza Vaccine (Split Virion) I. P

From the world leader in influenza vaccine\*



STOP FLU  
with  
**P.E.A.K.**  
PROTECTION


**With Latest WHO Recommended  
SH 2023 Flu Vaccine Strains Composition<sup>1</sup>**

Indicated for all persons **6 months** of age and older<sup>2</sup>

Demonstrated Robust Seroprotection against **H1N1, H3N2, and B Strains<sup>2,3</sup>**

**Split Virion Vaccine advantage** with more than 8 fold Increase in HAI Titres post Vaccination in Indian Children<sup>2,4</sup>

Provides Assurance of Quality as **FLUQUADRI®** is **India's 1<sup>st</sup> and only WHO prequalified** Quadrivalent Inactivated Flu Vaccine<sup>5</sup>



Please call your distributor or Sanofi personnel to place order Today

[Click Here](#)

For More Product Information Click Here  
 \*World's leading influenza vaccine company - based on revenue - Source: Statista (2022) (https://www.statista.com/chart/1000000/worlds-leading-influenza-vaccine-company)  
 1. WHO Weekly Epidemiol. Rec. (2023) 28(12): 1-25. Available from: https://www.who.int/docs/default-source/wer/20230128-28-12-20230128.pdf?sfvrsid=123456789  
 2. WHO Weekly Epidemiol. Rec. (2023) 28(12): 1-25. Available from: https://www.who.int/docs/default-source/wer/20230128-28-12-20230128.pdf?sfvrsid=123456789  
 3. WHO Weekly Epidemiol. Rec. (2023) 28(12): 1-25. Available from: https://www.who.int/docs/default-source/wer/20230128-28-12-20230128.pdf?sfvrsid=123456789  
 4. WHO Weekly Epidemiol. Rec. (2023) 28(12): 1-25. Available from: https://www.who.int/docs/default-source/wer/20230128-28-12-20230128.pdf?sfvrsid=123456789  
 5. WHO Weekly Epidemiol. Rec. (2023) 28(12): 1-25. Available from: https://www.who.int/docs/default-source/wer/20230128-28-12-20230128.pdf?sfvrsid=123456789

**sanofi** | Sanofi Healthcare India Pvt. Ltd.  
 Sanofi House, CTS No. 117-B, LBT Business Park, Saki Vihar Road, Powai, Mumbai - 400072, India.

Read the full article in the link below-

<https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/index.html#flu>

Reference: \*IAP ACVIP Influenza Vaccine <https://acvip.org/professional/columns/influenza-vaccine/> Last accessed on 06-04-2023

Note:

LAIV and IIV are different types of influenza vaccines:

**LAIV:** Live, attenuated influenza vaccine. It is a nasal spray that contains weakened live virus and is administered through the nostrils. LAIV is recommended for healthy children aged 2-18 years.

**IIV:** Inactivated influenza vaccine. It is an injection that contains killed virus and is administered into the muscle. IIV is recommended for all children aged 6 months to 5 years, and for persons with certain high-risk conditions from 6 to 18 years of age.

The information provided about LAIV and IIV influenza vaccines is based on the recommendations of the Advisory Committee on Immunization Practices (ACIP), which is a group of medical and public health experts in the United States that provides guidance on the use of vaccines.

For full prescribing information visit - <https://app.hidoc.co/5A87F1>

**sanofi**

**Sanofi Healthcare India (P) Ltd.**

Sanofi House CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072,  
Tel No. 022-28032000, Fax: 022-28032939